
ID: yalhkgcl,
Text: dexamethasone to the rescue

ID: pfr9xk6o,
Text: dexamethasone for pulpitis

ID: 6l0kb0v3,
Text: dexamethasone in the management of covid

ID: 7r7rzq36,
Text: dexamethasone in the management of covid

ID: cejdjwc5,
Text: dexamethasone in community acquired pneumonia

ID: tw3luwll,
Text: the use of dexamethasone in the treatment of covid

ID: 3ho8117q,
Text: coronavirus breakthrough dexamethasone is first drug shown to save lives

ID: 9ygpm1zz,
Text: coronavirus breakthrough dexamethasone is first drug shown to save lives

ID: mtscqxzv,
Text: covid demand for dexamethasone surges as recovery trial publishes preprint

ID: 71u261na,
Text: covid demand for dexamethasone surges as recovery trial publishes preprint

ID: bp9xz9wk,
Text: coronavirus

ID: vj000wal,
Text: coronavirus

ID: be0mr85h,
Text: coronavirus

ID: sfs5hsr9,
Text: coronavirus

ID: j1cdoxqs,
Text: coronavirus

ID: 3gjpqyfw,
Text: dexamethasone prednisone sodium chloride nosocomial legionellosis and invasive aspergillosis case report

ID: hxm86023,
Text: cancer recurrence and hyperglycemia with dexamethasone for postoperative nausea and vomiting prophylaxis more moot points

ID: dssr6eo9,
Text: dexamethasone acute respiratory distress syndrome secondary to strongyloides stercoralis infection case report

ID: b8p4l0yp,
Text: reducing dexamethasone antiemetic prophylaxis during the covid pandemic recommendations from ontario canada purpose people with cancer face an elevated risk of infection and severe sequelae from covid dexamethasone is commonly used for antiemetic prophylaxis with systemic therapy for cancer however dexamethasone is associated with increased risk of viral and respiratory infections and causes lymphopenia which is associated with worse outcomes during covid infections our purpose was to minimize dexamethasone exposure during antiemetic prophylaxis for systemic therapy for solid tumors during the covid pandemic while maintaining control of nausea and emesis methods we convened an expert panel to systematically review the literature and formulate consensus recommendations results no studies considered the impact of dexamethasone based antiemetic regimens on the risk and severity of covid infection expert consensus recommended modifications to the cancer care ontario antiemetic recommendations conclusion clinicians should prescribe the minimally effective dose of dexamethasone for antiemetic prophylaxis single day dexamethasone dosing is recommended over multi day dosing for regimens with high emetogenic risk excluding high dose cisplatin preferably in combination with palonosetron netupitant and olanzapine for regimens with low emetogenic risk ht antagonists are recommended over dexamethasone

ID: gd6dd4qm,
Text: reducing dexamethasone antiemetic prophylaxis during the covid pandemic recommendations from ontario canada purpose people with cancer face an elevated risk of infection and severe sequelae from covid dexamethasone is commonly used for antiemetic prophylaxis with systemic therapy for cancer however dexamethasone is associated with increased risk of viral and respiratory infections and causes lymphopenia which is associated with worse outcomes during covid infections our purpose was to minimize dexamethasone exposure during antiemetic prophylaxis for systemic therapy for solid tumors during the covid pandemic while maintaining control of nausea and emesis methods we convened an expert panel to systematically review the literature and formulate consensus recommendations results no studies considered the impact of dexamethasone based antiemetic regimens on the risk and severity of covid infection expert consensus recommended modifications to the cancer care ontario antiemetic recommendations conclusion clinicians should prescribe the minimally effective dose of dexamethasone for antiemetic prophylaxis single day dexamethasone dosing is recommended over multi day dosing for regimens with high emetogenic risk excluding high dose cisplatin preferably in combination with palonosetron netupitant and olanzapine for regimens with low emetogenic risk ht antagonists are recommended over dexamethasone
